🔍

LAXMIDENTL - Laxmi Dental

📊 NSE: LAXMIDENTL 🏢 Healthcare 📅 Last Updated: 12/14/2025 9:12

📢 Recent Corporate Announcements

Laxmi Dental to Participate in Investec India Investor Conference on March 11, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 27 Feb 2026, 11:52 AM

Laxmi Dental Limited has scheduled an interaction with institutional investors and analysts on March 11, 2026. The meeting is part of the Investec India Promoter & Founder Conference being held physically in Mumbai. The company will engage in 1x1 and group meetings starting from 10:00 AM. Management has clarified that no unpublished price sensitive information (UPSI) will be discussed during these sessions.

Meeting scheduled for March 11, 2026, starting at 10:00 AM IST.
Organized by Investec India as part of the Promoter & Founder Conference in Mumbai.
Interaction format includes both 1x1 and group meetings in physical mode.
Discussions will be strictly based on publicly available information as per SEBI regulations.

💡 Investors should monitor the company's website or exchange filings for any investor presentations that may be released following the conference. No immediate action is required as this is a routine corporate disclosure.

Laxmi Dental to Participate in Non-Deal Roadshow on March 5, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 26 Feb 2026, 07:12 PM

Laxmi Dental Limited has announced a Non-Deal Roadshow (NDR) scheduled for March 5, 2026, in Pune. The event, organized by Elara Capital, will feature 1x1 and group meetings with institutional investors starting from 11:00 AM. The company has explicitly stated that no unpublished price sensitive information (UPSI) will be discussed during these interactions. This move is part of the company's regular investor relations activities to engage with the financial community.

Non-Deal Roadshow (NDR) scheduled for March 5, 2026, in Pune.
Meetings will be conducted in 1x1 and group formats starting from 11:00 AM.
The event is being organized by Elara Capital for institutional investors.
Company confirms discussions will be based strictly on publicly available information.

💡 Investors should watch for any subsequent investor presentations or transcripts filed with the exchanges for insights into the company's strategy. No immediate trading action is required based on this routine disclosure.

Laxmi Dental Limited Releases Audio Recording of Q3FY26 Earnings Conference Call

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 11 Feb 2026, 02:54 PM

Laxmi Dental Limited has informed the exchanges that the audio recording of its Q3FY26 earnings conference call is now available for public access. The call was held on February 11, 2026, at 9:00 AM IST and was organized by Elara Securities. This disclosure is a standard compliance requirement under SEBI Listing Regulations to ensure transparency for all shareholders. Investors can access the recording via the link provided on the company's official website to hear management's commentary on the quarter's performance.

Audio recording of the Q3FY26 earnings call released on February 11, 2026.
The conference call was organized by Elara Securities (India) Private Limited.
Filing made pursuant to Regulation 30(6) of SEBI Listing Regulations.
Direct MP3 link provided for investor access on the company's website.

💡 Investors should listen to the recording to understand management's outlook on the dental export market and specific financial drivers for Q3FY26. This is a routine update and does not change the fundamental view of the stock unless new material information is discovered in the call.

Laxmi Dental Q3 Revenue Up 7.1% YoY to ₹660 Mn; PAT Drops 59% on Exceptional Item

🔵 WATCH ⭐ 7/10

EARNINGS 📅 10 Feb 2026, 09:49 PM

Laxmi Dental reported a 7.1% YoY revenue growth in Q3FY26, reaching ₹660.4 million, driven by strong international lab business growth of 25.5%. However, PAT declined significantly by 59.3% YoY to ₹19.6 million, primarily due to a one-time exceptional provision of ₹57.8 million for gratuity liabilities under new labour codes. EBITDA margins compressed to 10.6% from 15.6% a year ago, impacted by higher US tariffs (150 bps) and ESOP expenses. Management remains optimistic about Q4 recovery in the domestic market and normalization of pricing pressures in the aligner segment.

Revenue grew 7.1% YoY to ₹660.4 Mn in Q3FY26; 9M FY26 revenue up 14.3% to ₹2,039 Mn.
PAT fell 59.3% YoY to ₹19.6 Mn, impacted by a ₹57.8 Mn exceptional item for labour code compliance.
International dental lab business showed robust growth of 25.5% YoY, offsetting soft domestic performance.
EBITDA margins stood at 10.6%, affected by 150 bps impact from US tariffs and ₹16.14 Mn ESOP expenses.
Gross profit margins remained steady at 69.5% with sequential improvement due to lower low-margin scanner sales.

💡 Investors should monitor the recovery in domestic lab and aligner segments in Q4, as management indicates positive trends starting January 2026. While one-time costs hit the bottom line, the strong international growth and strategic positioning in digital dentistry remain key long-term drivers.

Laxmi Dental Q3FY26 Revenue Up 7% to ₹660 Mn; PAT Impacted by ₹57.8 Mn Exceptional Item

🔵 WATCH ⭐ 7/10

EARNINGS 📅 10 Feb 2026, 09:41 PM

Laxmi Dental reported a 7.1% YoY revenue growth to ₹660.4 Mn for Q3FY26, supported by a robust 25.5% growth in its international dental lab business. However, net profit fell 59.3% YoY to ₹19.6 Mn, primarily dragged down by a one-time exceptional provision of ₹57.8 Mn for gratuity liabilities under the new labour code. EBITDA margins were also pressured by higher US tariffs (150 bps impact) and increased ESOP expenses. Despite these headwinds, the company saw a ₹32.2 Mn deferred tax credit from its US subsidiary and expects a stronger Q4 recovery.

Consolidated Revenue grew 7.1% YoY to ₹660.4 Mn in Q3FY26, with 9M FY26 revenue up 14.3% to ₹2,039 Mn.
International lab business delivered 25.5% YoY growth, while domestic lab business remained soft during the quarter.
EBITDA margin contracted to 10.6% from 15.6% YoY due to ₹16.1 Mn ESOP costs and global macroeconomic challenges.
A one-time exceptional provision of ₹57.8 Mn was recorded for gratuity past service liability under the new labour code.
Scanner sales grew 46% YoY in Q3, acting as a strategic lead generator for the higher-margin lab and aligner segments.

💡 Investors should focus on the normalization of US tariffs and the management's guidance for a robust Q4 recovery in domestic segments. While one-time provisions hurt the bottom line, the strong growth in international markets and digital dentistry (scanners) remains a positive long-term indicator.

Laxmi Dental Reports Q3 FY26 Revenue of ₹477.7M; Net Loss of ₹18.9M on Exceptional Labour Code Costs

🔴 NEGATIVE ⭐ 7/10

EARNINGS 📅 10 Feb 2026, 07:10 PM

Laxmi Dental reported a year-on-year revenue growth of 11.7% for Q3 FY26, reaching ₹477.74 million. However, the company swung to a net loss of ₹18.90 million for the quarter, compared to a profit of ₹32.14 million in the same period last year. This loss was primarily driven by a one-time exceptional item of ₹51.56 million related to gratuity provisions under the New Labour Codes. For the nine-month period, net profit stands at ₹125.40 million, a significant decline from ₹215.99 million in the previous year.

Revenue from operations grew 11.7% Y-o-Y to ₹477.74 million, though it declined 11.1% on a Q-o-Q basis.
Reported a Net Loss of ₹18.90 million in Q3 FY26 vs a Net Profit of ₹32.14 million in Q3 FY25.
Recognized a one-time exceptional expense of ₹51.56 million for incremental gratuity impact following New Labour Code notifications.
Employee benefit expenses increased by 30% Y-o-Y to ₹200.91 million.
Utilized ₹669.78 million of IPO proceeds to date, with ₹611.92 million currently held in fixed deposits.

💡 Investors should treat the net loss as largely non-recurring due to the one-time labour code provision, but should monitor the sequential decline in revenue. Watch for stabilization in operating margins and the deployment of remaining IPO funds for growth.

Laxmi Dental Schedules Q3FY26 Earnings Conference Call for February 11, 2026

🟡 NEUTRAL ⭐ 4/10

EARNINGS 📅 04 Feb 2026, 05:04 PM

Laxmi Dental Limited has announced its earnings conference call for the third quarter of FY26, scheduled for February 11, 2026, at 09:00 AM IST. The management team, including the CEO and CFO, will discuss the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. This call is a standard post-earnings event hosted by Elara Securities to provide transparency on company performance. Investors can participate via the provided dial-in numbers or the Diamond Pass registration link.

Earnings conference call scheduled for February 11, 2026, at 09:00 AM IST.
Discussion will cover unaudited financial results for Q3 and 9M ended December 31, 2025.
Top management including Chairperson Rajesh Khakhar and CEO Sameer Merchant will be in attendance.
The call is being coordinated by Elara Securities (India) Private Limited.
Universal dial-in numbers provided are +91 22 6280 1146 and +91 22 7115 8047.

💡 Investors should review the financial results once released and attend the call to understand management's commentary on margin trends and growth outlook. Focus on updates regarding the dental export business and domestic expansion plans.

Laxmi Dental Clarifies No Undisclosed Information Behind Recent Trading Volume Surge

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 21 Jan 2026, 02:44 PM

Laxmi Dental Limited has issued a clarification to the Bombay Stock Exchange regarding a recent surge in its share trading volume on January 21, 2026. The company stated that it is in full compliance with Regulation 30 of SEBI LODR and has disclosed all relevant information to the exchanges. Management confirmed that there is no unpublished price sensitive information (UPSI) that could have triggered the volume movement. The company maintains that the recent trading activity is purely market-driven and not based on any internal developments.

Responded to BSE inquiry Ref: L/SURV/ONL/PV/APJ/ 2025-2026 / 876 dated January 21, 2026
Confirmed no pending disclosures under Regulation 30 of SEBI LODR Regulations
Stated that all share volume movements are purely market-driven
Reiterated commitment to maintaining transparency and timely disclosures

💡 Investors should view this as a routine regulatory clarification and avoid speculating on price or volume movements that lack fundamental backing. Focus on the company's quarterly performance and long-term growth prospects instead of short-term trading volatility.

Laxmi Dental Clarifies on Trading Volume Spurt; No Undisclosed Information

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 20 Jan 2026, 07:40 PM

Laxmi Dental Limited has responded to a clarification request from the National Stock Exchange regarding a significant increase in trading volume observed on January 20, 2026. The company officially stated that it has no unpublished price sensitive information (UPSI) that needs to be disclosed to the market. Management confirmed that all required disclosures under Regulation 30 of SEBI LODR are up to date. The company maintains that the recent surge in trading volume is purely market-driven and not linked to any undisclosed corporate developments.

NSE sought clarification on January 20, 2026, regarding a significant spurt in trading volume.
Company confirmed compliance with Regulation 30 of SEBI (LODR) Regulations, 2015.
Management explicitly stated there is no pending unpublished price sensitive information (UPSI).
The volume movement in the company's security is attributed to purely market-driven factors.
The response was signed and submitted by the Chief Financial Officer, Dharmesh Dattani.

💡 Investors should view this as a routine regulatory response and avoid speculating on the volume surge as the company has denied any undisclosed material events. Focus on upcoming quarterly results and fundamental growth drivers instead of short-term volume volatility.

Laxmi Dental Fined ₹2.06 Lakh by NSE for Compliance Lapse; Appoints New Company Secretary

🔴 NEGATIVE ⭐ 4/10

REGULATORY 📅 16 Jan 2026, 08:05 PM

Laxmi Dental Limited has been penalized by the National Stock Exchange (NSE) with a fine of ₹2,06,500 for a 35-day delay in filing Related Party Transaction disclosures for the half-year ended September 30, 2025. The company attributed the non-compliance to an administrative oversight during the absence of a dedicated Company Secretary. In response, the Board has appointed Mr. Suman Saha as the new Company Secretary and Compliance Officer to ensure future regulatory adherence. The company has also formally applied for a waiver of the fine, noting that the disclosures were correctly filed on the BSE.

NSE imposed a fine of ₹5,000 per day for 35 days of non-compliance with Regulation 23(9).
Total fine amount including 18% GST stands at ₹2,06,500 as of December 16, 2025.
The lapse occurred due to an oversight in verifying system-generated acknowledgments while the Compliance Officer was on leave.
Mr. Suman Saha has been appointed as the new Company Secretary and Compliance Officer effective January 16, 2026.
A formal waiver request has been submitted to the NSE, citing that information was disseminated on other platforms.

💡 While the fine is financially immaterial to the company's operations, investors should monitor the new Compliance Officer's ability to prevent future administrative lapses. No immediate portfolio action is required as the company has addressed the vacancy and filed for a waiver.

Laxmi Dental Appoints Suman Saha as Company Secretary and Compliance Officer

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 16 Jan 2026, 07:50 PM

Laxmi Dental Limited has announced the appointment of Mr. Suman Saha as the Company Secretary and Compliance Officer, effective January 16, 2026. Mr. Saha is a qualified Company Secretary and Law Graduate with extensive experience in corporate governance and regulatory matters. He has previously held senior roles at Lodha Group, OPPO Mobiles, and Sahara Group. This appointment fulfills a Key Managerial Personnel (KMP) requirement under SEBI regulations.

Appointment of Mr. Suman Saha as Company Secretary and Compliance Officer effective January 16, 2026
Mr. Saha is an Associate Member of ICSI (A33035) and a Law Graduate from the University of Mumbai
Professional background includes leadership roles at Lodha Group, OPPO Mobiles, Sahara Group, and IL&FS Group
Authorized as an official for determining materiality of events under Regulation 30(5) of SEBI Listing Regulations

💡 This is a routine administrative appointment to ensure regulatory compliance and corporate governance. No immediate action is required as it does not impact the company's core business operations or financial outlook.

Laxmi Dental Announces Conversion of Statutory Auditors M S K A & Associates to LLP

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 16 Jan 2026, 03:39 PM

Laxmi Dental Limited has notified the stock exchanges regarding a change in the legal constitution of its Statutory Auditors. The auditing firm, M S K A & Associates, has converted from a partnership firm into a Limited Liability Partnership (LLP) effective January 13, 2026. The firm will now operate under the name M S K A & Associates LLP with the ICAI registration number 105047W/W101187. This is a purely administrative change and does not affect the existing audit engagement or the auditor's tenure.

Statutory Auditor M S K A & Associates converted to M S K A & Associates LLP effective January 13, 2026.
The conversion was carried out under the provisions of the Limited Liability Partnership Act, 2008.
The ICAI Firm Registration number for the new entity is 105047W/W101187.
There is no change in the audit engagement terms or the remaining tenure of the auditors.

💡 No action is required from investors as this is a routine administrative update concerning the legal structure of the company's service provider.

Laxmi Dental Submits SEBI Reg 74(5) Compliance Certificate for Q3 FY26

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 08 Jan 2026, 05:37 PM

Laxmi Dental Limited has filed its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. The certificate, issued by MUFG Intime India Private Limited, confirms the processing of dematerialization requests for the quarter ended December 31, 2025. It verifies that security certificates received were mutilated and cancelled after due verification within prescribed timelines. This is a standard administrative filing ensuring the integrity of the company's shareholding records.

Compliance certificate submitted for the quarter ended December 31, 2025.
Confirmation provided by Registrar and Share Transfer Agent, MUFG Intime India Private Limited.
Verified that physical share certificates were mutilated and cancelled after dematerialization.
Ensured the name of depositories was substituted in the register of members as per SEBI norms.

💡 This is a routine regulatory update with no impact on company fundamentals. No specific action is required from investors.

Laxmi Dental to Host Analyst and Institutional Investor Meeting on January 13, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 08 Jan 2026, 04:15 PM

Laxmi Dental Limited has scheduled a virtual meeting with analysts and institutional investors on January 13, 2026, starting at 1:00 PM. The interaction will consist of 1x1 and group meetings to discuss company performance based on publicly available data. The company has explicitly stated that no unpublished price sensitive information (UPSI) will be shared during these sessions. This is a standard investor relations activity aimed at maintaining transparency with the market.

Virtual investor meeting scheduled for January 13, 2026, from 01:00 PM onwards.
Interaction format includes both 1x1 and group meetings with various participants.
Discussions will be strictly based on publicly available information to ensure compliance.
The meeting is organized under Regulation 30 of SEBI (LODR) Regulations, 2015.

💡 No immediate action is required as this is a routine investor engagement. Investors may check the company website later for any presentation materials or transcripts that might be uploaded.

Laxmi Dental Approves INR 50 Lakh Loan to Subsidiary at 10.5% Interest

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 29 Dec 2025, 03:32 PM

Laxmi Dental Limited has entered into a loan agreement to provide financial support to its 88.88% owned subsidiary, Signature Smiles Dental Clinic Private Limited. The agreement allows for a loan of up to INR 50 Lakhs to be disbursed in one or more tranches for general corporate purposes. The loan carries an interest rate of 10.50% per annum with a maximum tenor of five years. As of the disclosure date, the total outstanding loan amount to this subsidiary stands at INR 100 Lakhs, including interest.

Loan amount of up to INR 50 Lakhs granted to subsidiary Signature Smiles Dental Clinic.
Interest rate set at 10.50% per annum with a maximum repayment tenor of 5 years.
The transaction is an unsecured, arm's length related party transaction.
Current total outstanding loan to the subsidiary is reported at INR 100 Lakhs.
Laxmi Dental holds a significant 88.88% stake in the borrowing entity.

💡 This is a routine inter-corporate loan to support a subsidiary's operations and is relatively small in scale. Investors should treat this as a standard business support activity with no immediate impact on the stock's valuation.

View All LAXMIDENTL Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Laboratory business revenue grew 28% YoY to INR 94.0 Cr in H1 FY26. Aligner solutions (Bizdent) grew 7% YoY to INR 38.8 Cr. Scanner sales saw a massive jump of 94.7% YoY in Q2 FY26, with units sold in H1 FY26 already exceeding the total sold in FY25.

Geographic Revenue Split

In H1 FY26, domestic revenue was INR 43.4 Cr (up 13% YoY) and international revenue was INR 36.1 Cr (up 25% YoY). International growth is outpacing domestic growth as the company leverages its US FDA registration for global expansion.

Profitability Margins

Gross profit for Q2 FY26 stood at INR 49.5 Cr, reflecting 14.5% YoY growth. PAT margin for Q2 FY26 was 11.8%, while H1 FY26 PAT margin was 12.2%. The company targets a long-term EBITDA margin of 20%.

EBITDA Margin

EBITDA margin for Q2 FY26 was 15.3%, while H1 FY26 EBITDA margin was higher at 16.6%. Margins were impacted by a 90 bps headwind due to US tariffs on international sales.

Capital Expenditure

The company undertook a CAPEX of approximately INR 6 Cr in H1 FY26. It has INR 64 Cr in unutilized IPO proceeds earmarked for future capacity expansion and automation.

Credit Rating & Borrowing

The company is currently debt-free, having paid off its entire debt in H1 FY26. This significantly reduced finance costs, which were INR 5.39 Cr in FY25, improving overall net profitability.

⚙️ Operational Drivers

Raw Materials

Key raw materials include Zirconia blocks for crowns, polymer sheets (Taglus) for aligners, and digital scanner hardware components. Raw material costs are estimated at approximately 32% of revenue based on a 68% gross margin.

Import Sources

International markets, specifically the US and Germany, are key sources for technology and materials, as evidenced by US tariff impacts and participation in the IDS Germany event.

Capacity Expansion

The company is focusing on automation and R&D to enhance manufacturing capacities. It plans to deploy INR 64 Cr of unutilized IPO funds for future CAPEX to meet rising demand.

Raw Material Costs

Raw material costs represent approximately 32% of revenue. Procurement strategies focus on vertical integration (e.g., Taglus for aligners) to maintain high gross margins of ~68%.

Manufacturing Efficiency

The company is transitioning to digital dentistry; scanner sales jumped 94.7% YoY, which improves long-term efficiency by digitizing the impression-to-production cycle.

📈 Strategic Growth

Expected Growth Rate

20-25%

Growth Strategy

Growth will be achieved by scaling the branded product portfolio (Illusion Zirconia, Taglus), expanding manufacturing capacity through automation, and deepening international penetration following US FDA registration. The company uses lower-margin scanner sales as a strategic 'hook' to drive high-margin digital lab and aligner volumes.

Products & Services

Dental laboratory products (Zirconia crowns, bridges), clear aligners (Illusion Aligners), intra-oral scanners, and paediatric dental solutions (Kids-E-Dental).

Brand Portfolio

Illusion Zirconia, Illusion Aligners, Taglus, Bizdent, Vedia, and Kids-E-Dental.

New Products/Services

Intra-oral scanners are the primary new growth driver, with H1 FY26 sales already exceeding the total units sold in FY25. AI-driven diagnostics are also being integrated into the workflow.

Market Expansion

Targeting international markets with US FDA registration and EOU certification. Domestic expansion focuses on deepening the existing dental professional network.

Market Share & Ranking

Laxmi Dental is the second largest player in the domestic laboratory business and the largest export laboratory in India.

Strategic Alliances

Joint Ventures include Kids-E-Dental LLP (paediatric focus) and IDBG AI Dent (AI focus).

🌍 External Factors

Industry Trends

The industry is growing at ~20% and shifting toward digital dentistry and AI. Consolidation is occurring as organized players gain share from unorganized regional labs due to stricter regulatory norms and rising consumer awareness.

Competitive Landscape

Key organized competitors include DentCare (South India), alongside numerous regional unorganized labs that are currently facing consolidation pressures.

Competitive Moat

The moat is based on being the only integrated dental products company in India, providing a cost and quality advantage. Brand equity from celebrity endorsements and the scale of being the largest export lab provide durable competitive advantages.

Macro Economic Sensitivity

Highly sensitive to global trade policies; US tariffs resulted in a 90 bps margin compression in H1 FY26.

Consumer Behavior

Rising dental awareness and a shift toward branded, high-quality dental solutions are driving demand for the company's premium Illusion and Taglus brands.

Geopolitical Risks

Trade barriers and tariffs, particularly in the US market, pose a risk to the export-heavy laboratory business (INR 36.1 Cr in H1 FY26).

⚖️ Regulatory & Governance

Industry Regulations

Operations are governed by US FDA registration for exports, EOU (Export Oriented Unit) certification, and stricter domestic regulatory norms for dental medical devices.

Taxation Policy Impact

The effective tax rate was approximately 20.2% in FY25 (INR 64.5 Mn tax on INR 318.3 Mn PBT).

⚠️ Risk Analysis

Key Uncertainties

Key risks include global economic volatility affecting scanner adoption and potential fluctuations in international trade tariffs impacting export margins by ~90 bps.

Geographic Concentration Risk

International markets account for approximately 45% of core laboratory and aligner revenue, creating exposure to global trade dynamics.

Technology Obsolescence Risk

The company mitigates technology risk by aggressively investing in AI and digital scanners to stay ahead of the industry shift toward digital dentistry.